Moderna, COVID-19 and US Patent
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
5h
Zacks Investment Research on MSNHere's Why Moderna Stock Soared 16% on WednesdayShares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results